RxDoctor Payments Data

Bassim Assioun, MD

Nephrology · O Fallon, ILNPI 1669785408

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 41 payments — averaging $33.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$269
  • Novo Nordisk$238
  • Mallinckrodt Hospital Products Inc.$151
  • Globus Medical$132
  • Nevro Corp.$123
  • Sanofi$100
  • plus $353 from 9 others

What the payments were for

  • Food & beverage$1,30596%
  • Education$604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,365 in reported general payments places this provider in the 60th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$330,678
Medicare patients
711
Services billed
2,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol143$171,230
JardianceEmpagliflozin61$76,142
VelphoroSucroferric Oxyhydroxide12$36,075
LokelmaSodium Zirconium Cyclosilicate18$14,752
Sevelamer Carbonate44$9,830
Cinacalcet Hcl32$5,926
Allopurinol611$4,679
Potassium Citrate ErPotassium Citrate48$4,055
Febuxostat21$3,189
Calcitriol182$3,057
Potassium Chloride123$2,689
Bumetanide57$2,283
Potassium Citrate-Citric AcidPotassium Citrate/Citric Acid12$1,769
Hydralazine Hcl124$1,692
Losartan Potassium168$1,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$269$185,983161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 524 nephrology providers in Illinois.

Other nephrology in O Fallon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →